articleTop 1% cited

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

Gynecologic Oncology · 2011 · Vol. 121(2) · pp. 353–357

Shiyu Zhang(University of Toronto)Robert E. Royer(University of Toronto)Song Li(Women's College Hospital)Esther M. John(Lunenfeld-Tanenbaum Research Institute)Barry P. Rosen(University of Toronto)Harvey A. Risch(Yale University)Isabel Fan(Lunenfeld-Tanenbaum Research Institute)Linda Bradley(Lunenfeld-Tanenbaum Research Institute)Patricia A. Shaw(University of Toronto)Steven A. Narod✉(Women's College Hospital)

View via DOI Publisher page

BRCA gene mutations in cancer Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapyOvarian cancerMedicineMultiplex ligation-dependent probe amplificationSerous fluidGermline mutationOncologyBreast cancerCancerMutationPopulation

MeSH terms

AdultAge FactorsAgedFemaleHumansMiddle AgedNeoplasm InvasivenessOntarioOvarian NeoplasmsPrevalenceGerm-Line MutationGenes, BRCA1Genes, BRCA2Young Adult

Funding

Canadian Institutes of Health Research
National Cancer Institute

Citations

417

FWCI

17.00

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology · 2017 · 1,842 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.